Endometrial Cancer Therapeutics Market

Endometrial Cancer Therapeutics Market is estimated to Witness Growth Due to Rising Prevalence of Endometrial Cancer among Postmenopausal Women

by

Endometrial cancer also known as uterine cancer develops in the inner lining of the uterus called the endometrium. It is one of the most common gynecological cancers affecting women. Endometrial cancer treatments include surgical methods like hysterectomy, radiation therapy, chemotherapy, hormone therapy and targeted therapy. The global endometrial cancer market is primarily driven by the rising prevalence of endometrial cancer among postmenopausal women. According to statistics, endometrial cancer is the fourth most common cancer among women in the United States with an estimated 65,620 new cases in 2022. In addition, factors such as growing awareness about early cancer diagnosis, availability of advanced screening and diagnostic procedures are fueling the market growth.

 

The Global Endometrial Cancer Therapeutics Market is estimated to be valued at US$ 1.3 billion in 2027 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023-2027.

Key Takeaways

Key players operating in the endometrial cancer market are Pfizer, Merck, Bristol Myers Squibb, Johnson & Johnson, AstraZeneca, GlaxoSmithKline, and Novartis.

Increasing research and development activities for developing novel treatment drugs and modalities is expected to create lucrative opportunities in the market.

Rising healthcare expenditure along with growing need for effective cancer treatment in developing regions will drive the global expansion of the endometrial cancer market in the coming years.

Market Drivers

The rising prevalence of obesity is considered as a major risk factor for endometrial cancer. It is estimated that nearly 50-60% of endometrial cancer cases are linked to excess body weight or obesity. Postmenopausal women who are overweight or obese have two to four times higher risk of developing endometrial cancer as compared to those with normal weight. This increasing rate of obesity in women worldwide due to sedentary lifestyle is expected to fuel the growth of the global endometrial cancer market during the forecast period.

PEST Analysis

Political: Endometrial cancer screening and treatment is supported by governments through various healthcare programs and initiatives that aim to improve women’s health. This provides access to diagnosis and care.
Economic: The overall costs of endometrial cancer to the healthcare system is significant. New drugs and therapeutics can be expensive to develop but help reduce spending on late-stage treatment if effective preventive strategies are pursued.
Social: As women delay childbearing, the incidence of endometrial cancer is increasing. Public awareness drives help improve lifestyle choices that may influence risk factors. Greater social support eases the physical and mental burden of women undergoing treatment.
Technological: Advancements in minimally invasive surgical procedures allow for fertility-sparing treatment in early-stage disease. Molecular diagnostics and targeted therapies provide customized, precision care. Telehealth expands remote screening options and supports patients.

Geographical Regions:

The market for endometrial cancer treatment is primarily concentrated in developed countries where accessible healthcare and aging populations drive demand. North America accounts for the largest share globally due to factors such as sophisticated healthcare infrastructure and high treatment costs in the United States. Western Europe is another major regional market with Germany, France and the UK among the top countries. Availability of private health insurance aids market growth.

Fastest growing region:

The Asia Pacific region is poised to experience the fastest rise in the endometrial cancer market over the coming years. This is because countries like China and India are witnessing significant increases in per capita income and healthcare expenditure. Additionally, lifestyle changes associated with economic development are leading to growth in risk factors in the general population. Greater affluence is supporting improved diagnosis and investment in cutting-edge therapeutics from international drug makers. Coordinated efforts can help curtail future disease burden through widespread screening programs.

What Are The Key Data Covered In This Endometrial Cancer Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Endometrial Cancer’s growth between 2024 and 2031.

:- Accurate calculation of the size of the Endometrial Cancer and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Endometrial Cancer Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Endometrial Cancer vendors

 

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

About Author – Alice Mutum
+ posts

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice’s dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights. LinkedIn